Edition:
United Kingdom

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

6.77USD
3:46pm GMT
Change (% chg)

$0.88 (+14.94%)
Prev Close
$5.89
Open
$5.92
Day's High
$6.77
Day's Low
$5.92
Volume
19,982
Avg. Vol
42,232
52-wk High
$10.46
52-wk Low
$5.44

Select another date:

Wed, Nov 8 2017

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update

BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema

BRIEF-Clearside Biomedical reports Q2 loss per share $0.54

* Announces second quarter 2017 financial results and provides corporate update

BRIEF-Clearside Biomedical completes patient enrollment in Phase 3 Peachtree Clinical Trial of CLS-TA

* Announces completion of patient enrollment in pivotal Phase 3 Peachtree Clinical Trial of CLS-TA for Suprachoroidal administration in patients with Macular Edema associated with non-infectious Uveitis

BRIEF-Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema

BRIEF-Clearside Biomedical files for mixed shelf offering of up to $250 mln - SEC Filing‍​ ‍​

* Clearside Biomedical Inc files for mixed shelf offering of up to $250 million - SEC Filing‍​ ‍​ Source text: [http://bit.ly/2tDFDPJ] Further company coverage:

BRIEF-Clearside Biomedical ‍on June 30, entered into sales agreement with Cowen and Company, LLC - SEC Filing​

* Clearside Biomedical Inc - ‍on June 30, 2017, Clearside Biomedical, Inc. entered into sales agreement with Cowen and Company, LLC - SEC Filing​

Select another date: